And some relatively infrequent KIFs-suppressors, including pan kinesin-13 members targeted inhibitor DHTP [178], and KIF2C depressor Sulfoquinovosylacylglycerols (SQAGs) [179], KIF20A targeted suppressor paprotrain [180], KIF18A contraposed inhibitor BTB-1 and its synthetic derivatives [181, 182], as well as allosteric inhibitors of KIFC1: AZ82, SR31527, and CW069 [183–185], etc. Regrettably, the verification of the anti-tumor effects of these targets is still in the preclinical stage, and also remain to be investigated for clinical activity against HBCs. This evidence concerns the gene KIF2C and neoplasm.